Tag: msk

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

Continue Reading Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

Researchers develop new machete technique to slice into cancer genome and study copy number alterations — ScienceDaily

MACHETE is a new CRISPR-based technique developed by researchers at the Sloan Kettering Institute (SKI) to study large-scale genetic deletions efficiently in laboratory models. People are already calling it the Machete Paper. Still, lead authors Francisco “Pancho” Barriga and Kaloyan Tsanov of the Sloan Kettering Institute don’t want the name…

Continue Reading Researchers develop new machete technique to slice into cancer genome and study copy number alterations — ScienceDaily

Bioinformatics Software Engineer I – Genomics | Memorial Sloan Kettering Cancer Center

Nationwide, Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes. We’re treating cancer, one patient at a time….

Continue Reading Bioinformatics Software Engineer I – Genomics | Memorial Sloan Kettering Cancer Center

Cell-Free DNA NGS Yields Low Detection in Metastatic ccRCC

Cell-free DNA-based next-general sequencing (NGS) yielded low detection rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to an analysis published in JCO Precision Oncology. Researchers performed NGS of tumor DNA and plasma DNA using the MSK-IMPACT platform in 110 patients with metastatic ccRCC. They explored detection…

Continue Reading Cell-Free DNA NGS Yields Low Detection in Metastatic ccRCC

Bioinformatics Software Engineer III in New York, NY for Memorial Sloan-Kettering Cancer Center

Details Posted: 05-Jul-22 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re…

Continue Reading Bioinformatics Software Engineer III in New York, NY for Memorial Sloan-Kettering Cancer Center

2022-60607 Bioinformatics Software Engineer I

Accessibility and Equal Opportunity If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are…

Continue Reading 2022-60607 Bioinformatics Software Engineer I

MSK Chief of the Lymphoma Service Gilles Sall

December 14, 2021, NEW YORK, NY – A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a…

Continue Reading MSK Chief of the Lymphoma Service Gilles Sall

Promising new treatment for patients with diffuse large B-cell lymphoma

Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin,…

Continue Reading Promising new treatment for patients with diffuse large B-cell lymphoma

BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors…

Continue Reading BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

Bioinformatics Software Engineer I – Memorial Sloan Kettering Cancer Center

At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes.  We’re treating cancer, one patient at a time. Join us and make a…

Continue Reading Bioinformatics Software Engineer I – Memorial Sloan Kettering Cancer Center

MSK Careers – Page Not Found

If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and…

Continue Reading MSK Careers – Page Not Found

2020-39864 Bioinformatics Software Engineer I

If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and…

Continue Reading 2020-39864 Bioinformatics Software Engineer I